Jun 27, 2024, 12:00 AM
Jun 27, 2024, 12:00 AM

Walgreens Reports Disappointing Earnings Amid Challenging Market Conditions

Highlights
  • Walgreens has announced a reduction in its profit forecast and plans to close several underperforming stores across the United States.
  • This decision is part of a broader strategy to cut costs in a challenging retail environment.
  • The company's performance reflects ongoing struggles in the pharmacy and convenience store market.
Story

Walgreens has announced its fiscal third-quarter earnings, which fell short of market expectations, prompting the company to revise its full-year adjusted profit outlook downward. The retail pharmacy giant cited a "challenging" environment for pharmacies and U.S. consumers as key factors influencing its performance. Following the announcement, Walgreens shares plummeted over 20%, reflecting investor concerns about the company's future profitability. Despite the disappointing earnings, Walgreens exceeded revenue estimates for the quarter, reporting $36.4 billion in sales, surpassing the anticipated $35.94 billion. This represents a 2.6% increase from the same period last year. The company’s net income for the quarter was $344 million, or 40 cents per share, a significant rise from $118 million, or 14 cents per share, in the previous year. The health-care segment, particularly through partnerships with VillageMD and Shields Health Solutions, contributed positively to this revenue growth. In the U.S. retail pharmacy segment, Walgreens generated $28.5 billion in sales, marking a 2.3% increase year-over-year. The growth in pharmacy sales, which rose by 4.4%, was driven by price inflation in brand medications and an increase in prescription volume. However, this was somewhat offset by a decline in retail revenue, indicating ongoing challenges in the broader retail environment. Looking ahead, Walgreens has adjusted its fiscal 2024 earnings forecast to between $2.80 and $2.95 per share, as the company seeks to navigate the current market landscape while focusing on its core retail pharmacy business.

Opinions

You've reached the end